Prelude Therapeutics (PRLD) Stock: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$3.67
-0.12 (-3.17%)
▼
5d:
-5.29%
30d:
-32.41%
90d:
-26.45%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRLD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PRLD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $3.67, which is considered oversold relative to its 30-day fair value range of $4.04 to $5.66. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.7) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a uptrend. The price is currently testing key support at $3.59. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.20 (+150.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRLD is in a uptrend. The price is currently testing key support at $3.59. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.20 (+150.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.04 -
$5.66
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 150.7% below Wall St target ($9.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
- CAUTION: 5-day price weakness (-5.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.04 -
$5.66
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.59
Resistance Level
$4.91
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.67
Wall Street Target
$9.20
(+150.7%)
Revenue Growth (YoY)
41.0%
Profit Margin
-269.8%
PE vs Historical
-6.7 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 11:15 AM ET
Data refreshes hourly during market hours. Next update: 12:15 PM
Data refreshes hourly during market hours. Next update: 12:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Bonita
BUY
2815315 shares
2026-04-21
Orbimed Advisors Llc
BUY
2815315 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
